Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ADIL
ADIL logo

ADIL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Adial Pharmaceuticals Inc (ADIL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.400
1 Day change
-5.14%
52 Week Range
18.900
Analysis Updated At
2026/05/28
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ADIL is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term momentum, but the move is already extended and the RSI is overbought. With no recent news, no strong institutional or insider buying, no option signal, and no favorable fundamental data available, this is not a high-conviction entry for a patient long-term allocation. I would not buy it now.

Technical Analysis

Price closed at 2.55, up 5.86% from the previous close of 2.39. Momentum is positive because the MACD histogram is above zero and expanding, and moving averages are converging, which can support continuation. However, RSI_6 at 80.006 signals the stock is overbought, so the current move looks stretched. Key resistance is near 2.739, with pivot at 1.967 and support at 1.489. The recent setup suggests near-term strength, but the entry is not attractive for a beginner who prefers long-term holding.

Positive Catalysts

  • ["MACD histogram is positive and expanding, showing improving momentum.", "Recent price action is strong, with the stock up 5.86% on the day.", "Pattern-based trend projection suggests possible short-term upside over the next day, week, and month."]

Neutral/Negative Catalysts

  • ["RSI_6 above 80 indicates the stock is overbought.", "No news in the last week, so there is no clear event-driven catalyst.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "Insiders are neutral with no significant activity over the last month.", "No valuation data and no usable financial snapshot were provided.", "No recent congress trading data available.", "AI Stock Picker has no signal today.", "SwingMax has no recent signal."]

Financial Performance

No financial snapshot was available because the provided financial data returned an error, so the latest quarter season and growth trends cannot be assessed from the supplied data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent Wall Street pros or cons shift to summarize.

Wall Street analysts forecast ADIL stock price to fall
1 Analyst Rating
Wall Street analysts forecast ADIL stock price to fall
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.530
sliders
Low
1.5
Averages
1.5
High
1.5
Current: 2.530
sliders
Low
1.5
Averages
1.5
High
1.5
Maxim
Buy
downgrade
$8
AI Analysis
2026-02-11
Reason
Maxim
Price Target
$8
AI Analysis
2026-02-11
downgrade
Buy
Reason
Maxim lowered the firm's price target on Adial Pharmaceuticals to $8 from $37.50 and keeps a Buy rating on the shares. The firm remains positive on the stock based on the AUD opportunity, as well as a potentially more favorable regulatory environment given Congressional activity in support of combating substance abuse, though its reduced price target reflects the reverse split and the expected dilution, the analyst tells investors in a research note.
Maxim
Hold
to
Buy
upgrade
$1.50
2025-09-30
Reason
Maxim
Price Target
$1.50
2025-09-30
upgrade
Hold
to
Buy
Reason
Maxim upgraded Adial Pharmaceuticals to Buy from Hold with a $1.50 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ADIL
Unlock Now

People Also Watch